 Christopher Nitkin
Concepts (81)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinopathy of Prematurity | 2 | 2023 | 3 | 1.820 |
Why?
| | Hypertension, Pulmonary | 2 | 2023 | 8 | 1.800 |
Why?
| | Mesenchymal Stem Cell Transplantation | 2 | 2019 | 3 | 1.290 |
Why?
| | Bronchopulmonary Dysplasia | 2 | 2022 | 39 | 0.920 |
Why?
| | Lipopolysaccharides | 2 | 2020 | 20 | 0.910 |
Why?
| | Proto-Oncogene Proteins c-fos | 2 | 2020 | 4 | 0.780 |
Why?
| | Neovascularization, Pathologic | 1 | 2020 | 6 | 0.760 |
Why?
| | Lung | 1 | 2020 | 65 | 0.730 |
Why?
| | Signal Transduction | 1 | 2020 | 107 | 0.730 |
Why?
| | Infant, Newborn, Diseases | 1 | 2019 | 32 | 0.670 |
Why?
| | Infant, Premature | 4 | 2023 | 81 | 0.650 |
Why?
| | Macrophages | 1 | 2017 | 4 | 0.630 |
Why?
| | Antioxidants | 1 | 2017 | 5 | 0.630 |
Why?
| | Animals | 5 | 2021 | 563 | 0.620 |
Why?
| | Inflammation | 1 | 2017 | 48 | 0.610 |
Why?
| | Infant, Newborn | 5 | 2023 | 790 | 0.590 |
Why?
| | Pediatrics | 1 | 2016 | 170 | 0.490 |
Why?
| | Humans | 9 | 2023 | 6599 | 0.470 |
Why?
| | Angiogenesis Inhibitors | 2 | 2023 | 4 | 0.460 |
Why?
| | Bevacizumab | 2 | 2023 | 3 | 0.460 |
Why?
| | Gestational Age | 2 | 2022 | 61 | 0.390 |
Why?
| | Diffusion of Innovation | 2 | 2019 | 7 | 0.320 |
Why?
| | Mice | 2 | 2020 | 290 | 0.320 |
Why?
| | Treatment Outcome | 2 | 2019 | 624 | 0.270 |
Why?
| | Retrospective Studies | 3 | 2023 | 1251 | 0.240 |
Why?
| | Intravitreal Injections | 1 | 2023 | 1 | 0.230 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2023 | 11 | 0.230 |
Why?
| | Lasers | 1 | 2022 | 1 | 0.230 |
Why?
| | Endothelial Growth Factors | 1 | 2022 | 1 | 0.230 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2022 | 5 | 0.230 |
Why?
| | Vasodilator Agents | 1 | 2022 | 3 | 0.220 |
Why?
| | Liver Diseases | 1 | 2023 | 17 | 0.220 |
Why?
| | Heart Defects, Congenital | 1 | 2023 | 81 | 0.210 |
Why?
| | Infant | 2 | 2023 | 1396 | 0.200 |
Why?
| | Cell Line | 1 | 2020 | 80 | 0.190 |
Why?
| | Gene Expression Regulation | 1 | 2020 | 98 | 0.180 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2021 | 67 | 0.180 |
Why?
| | Culture Media, Conditioned | 1 | 2017 | 2 | 0.160 |
Why?
| | Inflammation Mediators | 1 | 2017 | 8 | 0.160 |
Why?
| | Hyperoxia | 1 | 2017 | 4 | 0.160 |
Why?
| | Cells, Cultured | 1 | 2017 | 73 | 0.160 |
Why?
| | Cytokines | 1 | 2017 | 48 | 0.150 |
Why?
| | Gene Expression | 1 | 2017 | 60 | 0.150 |
Why?
| | Donor Selection | 1 | 2016 | 2 | 0.150 |
Why?
| | Phenotype | 1 | 2017 | 233 | 0.150 |
Why?
| | Age Factors | 1 | 2016 | 203 | 0.140 |
Why?
| | Postoperative Complications | 1 | 2016 | 177 | 0.130 |
Why?
| | Risk Factors | 1 | 2016 | 460 | 0.130 |
Why?
| | Male | 1 | 2022 | 3197 | 0.130 |
Why?
| | Female | 1 | 2022 | 3436 | 0.120 |
Why?
| | Child | 1 | 2022 | 3146 | 0.120 |
Why?
| | Bronchial Neoplasms | 1 | 2005 | 1 | 0.070 |
Why?
| | Receptors, Retinoic Acid | 1 | 2005 | 1 | 0.070 |
Why?
| | Respiratory Mucosa | 1 | 2005 | 4 | 0.070 |
Why?
| | Azacitidine | 1 | 2005 | 4 | 0.070 |
Why?
| | Lung Neoplasms | 1 | 2005 | 22 | 0.070 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2005 | 23 | 0.070 |
Why?
| | Parenteral Nutrition | 1 | 2023 | 7 | 0.060 |
Why?
| | Liver Cirrhosis | 1 | 2023 | 9 | 0.060 |
Why?
| | Bilirubin | 1 | 2023 | 25 | 0.060 |
Why?
| | Dexamethasone | 1 | 2022 | 30 | 0.050 |
Why?
| | Adrenal Cortex Hormones | 1 | 2022 | 34 | 0.050 |
Why?
| | Pilot Projects | 1 | 2022 | 124 | 0.050 |
Why?
| | Disease Models, Animal | 1 | 2021 | 55 | 0.050 |
Why?
| | Cell Differentiation | 1 | 2021 | 41 | 0.050 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2005 | 1 | 0.020 |
Why?
| | Transglutaminases | 1 | 2005 | 3 | 0.020 |
Why?
| | Tretinoin | 1 | 2005 | 2 | 0.020 |
Why?
| | Luciferases | 1 | 2005 | 6 | 0.020 |
Why?
| | GTP-Binding Proteins | 1 | 2005 | 7 | 0.020 |
Why?
| | Immunoblotting | 1 | 2005 | 11 | 0.020 |
Why?
| | Transfection | 1 | 2005 | 19 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2005 | 16 | 0.020 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2005 | 7 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2005 | 44 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2005 | 47 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 64 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2005 | 51 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2005 | 50 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2005 | 87 | 0.020 |
Why?
| | DNA Methylation | 1 | 2005 | 108 | 0.020 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|